Literature DB >> 31794600

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.

Marwan Kwok1,2,3, Ceri Oldreive1, Andy C Rawstron3, Anshita Goel1,4, Grigorios Papatzikas1,4, Rhiannon E Jones5, Samantha Drennan6, Angelo Agathanggelou1, Archana Sharma-Oates1,4, Paul Evans3, Edward Smith1, Surita Dalal3, Jingwen Mao1, Robert Hollows1, Naheema Gordon1, Mayumi Hamada1, Nicholas J Davies1, Helen Parry2,7, Andrew D Beggs1, Talha Munir3, Paul Moreton8, Shankara Paneesha9, Guy Pratt1,2, A Malcolm R Taylor1, Francesco Forconi6, Duncan M Baird5, Jean-Baptiste Cazier1,4, Paul Moss2,7, Peter Hillmen3,10, Tatjana Stankovic1.   

Abstract

Spontaneous regression is a recognized phenomenon in chronic lymphocytic leukemia (CLL) but its biological basis remains unknown. We undertook a detailed investigation of the biological and clinical features of 20 spontaneous CLL regression cases incorporating phenotypic, functional, transcriptomic, and genomic studies at sequential time points. All spontaneously regressed tumors were IGHV-mutated with no restricted IGHV usage or B-cell receptor (BCR) stereotypy. They exhibited shortened telomeres similar to nonregressing CLL, indicating prior proliferation. They also displayed low Ki-67, CD49d, cell-surface immunoglobulin M (IgM) expression and IgM-signaling response but high CXCR4 expression, indicating low proliferative activity associated with poor migration to proliferation centers, with these features becoming increasingly marked during regression. Spontaneously regressed CLL displayed a transcriptome profile characterized by downregulation of metabolic processes as well as MYC and its downstream targets compared with nonregressing CLL. Moreover, spontaneous regression was associated with reversal of T-cell exhaustion features including reduced programmed cell death 1 expression and increased T-cell proliferation. Interestingly, archetypal CLL genomic aberrations including HIST1H1B and TP53 mutations and del(13q14) were found in some spontaneously regressing tumors, but genetic composition remained stable during regression. Conversely, a single case of CLL relapse following spontaneous regression was associated with increased BCR signaling, CLL proliferation, and clonal evolution. These observations indicate that spontaneously regressing CLL appear to undergo a period of proliferation before entering a more quiescent state, and that a complex interaction between genomic alterations and the microenvironment determines disease course. Together, the findings provide novel insight into the biological processes underpinning spontaneous CLL regression, with implications for CLL treatment.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31794600     DOI: 10.1182/blood.2019001262

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

Review 2.  How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.

Authors:  Jennifer M Logue; Julio C Chavez
Journal:  Curr Treat Options Oncol       Date:  2021-10-26

3.  Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Maria Joao Baptista; Sivasubramanian Baskar; Erika M Gaglione; Keyvan Keyvanfar; Inhye E Ahn; Adrian Wiestner; Clare Sun
Journal:  Clin Cancer Res       Date:  2021-04-19       Impact factor: 13.801

4.  Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up.

Authors:  Xingnong Ye; Xiaofang Xiao; Bin Li; Weigang Zhu; Youjiang Li; Jianguo Wu; Xin Huang; Jingxia Jin; Dan Chen; Jie Jin; Jian Huang
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

Review 5.  Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.

Authors:  Marwan Kwok; Catherine J Wu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 6.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

Review 7.  Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.

Authors:  Marwan Kwok; Angelo Agathanggelou; Nicholas Davies; Tatjana Stankovic
Journal:  Cancers (Basel)       Date:  2021-09-18       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.